Antibodies | N | EULAR/ACR | EULAR/ACR punctuating non-Jo1 ARS† | Solomon |
Anti-Jo1 | 17 (100) | 17 (100) | 17 (100) | 11 (64.7) |
Anti-PL12 | 8 (100) | 2 (25) | 8 (100) | 2 (25) |
Anti-PL7 | 4 (100) | 0 (0) | 4 (100) | 1 (25) |
Anti-EJ | 4 (100) | 2 (50) | 4 (100) | 0 (0) |
Anti-OJ | 4 (100) | 1 (25) | 3 (75) | 3 (75) |
Total | 37 (100) | 22 (59.5) | 36 (97.2) | 17 (45.9) |
Bold and italic values indicate the number of cases with non-anti-Jo1 ARS that met EULAR/ACR criteria and those that are reclassified.
*Results are expressed as number (percentage).
†As a theoretical exercise, we assigned to each ARS the same weight as anti-Jo1 in the EULAR/ACR criteria.
ARS, antisynthetase antibodies; ASSD, antisynthetase syndrome; EULAR/ACR, European League Against Rheumatism/American College of Rheumatology classification criteria; IIM, idiopathic inflammatory myopathies.